Drug discovery companies identify, validate and develop new therapeutic candidates for the prevention and treatment of disease. The sector combines biology, chemistry, data science and clinical expertise to bring new medicines from concept to clinic.
This category includes companies working on:
Browse 422 UK drug discovery companies below.
Platform for controlled, repeatable cellular rejuvenation therapeutics
BioRes is a preclinical biotechnology company developing a platform for controlled, repeatable cellular rejuvenation. The company's approach aims to restore cellular function as a…
GPCR-targeted small molecule drugs for rare and inflammatory disease
Trio Medicines is a small pharmaceutical company developing small molecule therapeutics targeting G-protein coupled receptors for diseases with unmet clinical need. Its pipeline…
Rejuvenation biology company decoding the genomics of cellular ageing reversal
clock.health is a biotechnology company developing therapies to reverse cellular ageing and extend healthspan by decoding the biological programmes that govern cell rejuvenation.…
Antibody therapeutics targeting glycosphingolipid inflammation
Protalea Bio is a biotech company developing first-in-class therapeutic antibodies to prevent progression from precancerous states to active blood cancers including multiple…
Contract synthesis of custom and modified oligonucleotides
ATDBio is a UK-based contract oligonucleotide synthesis company specialising in chemically modified DNA and RNA oligonucleotides for therapeutic and diagnostic applications. Its…
Clinical-stage company developing radioligand cancer therapies
Blue Earth Therapeutics is a clinical-stage biotechnology company developing targeted radiopharmaceutical therapies for cancer. Its pipeline centres on prostate-specific membrane…
AAV gene therapy platform and clinical pipeline for genetic disease
AskBio UK Ltd is the European headquarters of AskBio Inc., a fully integrated AAV gene therapy company and Bayer AG subsidiary. Operating from Roslin Innovation Centre, the…
Antibody therapies targeting severe autoimmune diseases
argenx UK Ltd is the UK commercial subsidiary of argenx SE, a global immunology company developing antibody-based therapies for severe autoimmune diseases. The company markets…
Peptide immunotherapies for the treatment of food allergy
Aravax is a clinical-stage biotechnology company developing next-generation specific immunotherapies for food allergy. Its lead candidate, PVX108, is a synthetic peptide-based…
AI platform for pharma drug discovery workflows
DaltonTx is a technology company building adaptive AI-enabled discovery platforms for the pharmaceutical industry. Its disease- and modality-agnostic platform integrates into…
RNAi brain shuttle platform for neurodegenerative disease drug delivery
Aerska is a biotechnology company developing RNA interference medicines to treat, delay and prevent diseases of the brain. The company's antibody oligonucleotide conjugate…
3D immune-microtumour platform for cancer treatment selection
Pear Bio is a biotechnology company that tests cancer treatment efficacy directly on patient-derived tumour samples using three-dimensional immune-microtumour cultures and…